Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability

Enrico Munari; Giuseppe Zamboni; Marcella Marconi; Marco Sommaggio; Matteo Brunelli; Guido Martignoni; George J. Netto; Francesca Moretta; Maria Cristina Mingari; Matteo Salgarello; Alberto Terzi; Vincenzo Picece; Carlo Pomari; Gianluigi Lunardi; Alberto Cavazza; Giulio Rossi; Lorenzo Moretta; Giuseppe Bogina

doi:10.18632/oncotarget.26475

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability

PDF | How to cite

Oncotarget. 2018; 9:37077-37077. https://doi.org/10.18632/oncotarget.26475

Metrics: PDF 1691 views | ?

Enrico Munari^1,2, Giuseppe Zamboni¹, Marcella Marconi¹, Marco Sommaggio¹, Matteo Brunelli², Guido Martignoni^2,3, George J. Netto⁴, Francesca Moretta⁵, Maria Cristina Mingari⁶, Matteo Salgarello⁷, Alberto Terzi⁸, Vincenzo Picece⁹, Carlo Pomari¹⁰, Gianluigi Lunardi⁹, Alberto Cavazza¹¹, Giulio Rossi¹², Lorenzo Moretta¹³ and Giuseppe Bogina¹

¹ Department of Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy
² Department of Pathology AOUI, University of Verona, Verona, Italy
³ Department of Pathology, Pederzoli Hospital, Peschiera del Garda, Italy
⁴ Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA
⁵ Department of Laboratory Medicine, Sacro Cuore Don Calabria Hospital, Negrar, Italy
⁶ Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy
⁷ Department of Nuclear Medicine, Sacro Cuore Don Calabria Hospital, Negrar, Italy
⁸ Department of Thoracic Surgery, Sacro Cuore Don Calabria Hospital, Negrar, Italy
⁹ Department of Oncology, Sacro Cuore Don Calabria Hospital, Negrar, Italy
¹⁰ Department of Pulmonology, Sacro Cuore Don Calabria Hospital, Negrar, Italy
¹¹ Department of Pathology, Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia, Italy
¹² Department of Pathology, Azienda USL Valle d’Aosta, Aosta, Italy
¹³ Immunology Research Area, IRCCS Bambino Gesu Pediatric Hospital, Rome, Italy

Published: December 11, 2018

This article has been corrected: In the Materials and Methods section, regarding theTissue Microarray Construction, the diameter of the TMA core is incorrect. The proper value should be 1 mm, not 0.6 mm, as shown below:

Tissue microarray construction

For every case, all H&E stained slides were reviewed for diagnosis confirmation; one block was then selected for tissue microarray (TMA) construction. It has been demonstrated that TMAs containing at least 3 cores per case yield satisfactory agreement compared with whole section in lung cancer [14]. Therefore, for each block, 5 cores with a diameter of 1 mm were obtained randomly from the diverse areas of the tumor. Overall, 11 TMAs were built.

Original article: Oncotarget. 2017; 8:90123-90131. DOI: https://doi.org/10.18632/oncotarget.21485.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26475

Publication Alerts

Corrections:

Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability